Welcome to our dedicated page for INVO BioScience news (Ticker: INVO), a resource for investors and traders seeking the latest updates and insights on INVO BioScience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INVO BioScience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INVO BioScience's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
INVO Bioscience (NASDAQ: INVO) reported its financial results for Q4 and FY 2022, indicating a revenue of
INVO Bioscience (NASDAQ: INVO) is set to announce its financial results for Q4 and fiscal year 2022, ending December 31, 2022, after market close on
Summary not available.
INVO Bioscience, Inc. (NASDAQ: INVO) reported preliminary financial results for Q4 and the full year of 2022. Q4 revenue is expected to increase by 15% to 19%, projecting between $270,000 and $280,000, compared to $235,321 in Q3. Full-year revenue for 2022 is anticipated to rise 38% to 40%, estimating $815,000 to $825,000, up from $588,687 in 2021. However, gross revenue for 2022 is expected to decline by roughly 80% due to the termination of a licensing agreement. INVO also reported ongoing clinic revenue growth and the execution of a significant clinic acquisition, aimed at enhancing their business strategy.